Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-04-10
2007-04-10
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C536S024330
Reexamination Certificate
active
10484441
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of diseases associated with expression of acyl CoA cholesterol acyltransferase-2 are provided.
REFERENCES:
patent: 5484727 (1996-01-01), Chang et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5968749 (1999-10-01), Chang et al.
patent: 5985558 (1999-11-01), Dean et al.
patent: 6001992 (1999-12-01), Ackermann et al.
patent: 6020199 (2000-02-01), Monia et al.
patent: 6046049 (2000-04-01), Monia et al.
patent: 6100077 (2000-08-01), Sturley et al.
patent: 6124133 (2000-09-01), Taylor et al.
patent: 6133032 (2000-10-01), Monia et al.
patent: 6136603 (2000-10-01), Dean et al.
patent: 6140124 (2000-10-01), Monia et al.
patent: 6140126 (2000-10-01), Bennett et al.
patent: 6180353 (2001-01-01), Dean et al.
patent: 6482644 (2002-11-01), Cowsert
patent: 6503754 (2003-01-01), Zhang et al.
patent: 6579974 (2003-06-01), Cases et al.
patent: 6613567 (2003-09-01), Bennett et al.
patent: 6656688 (2003-12-01), Bennett et al.
patent: 6656732 (2003-12-01), Bennett et al.
patent: 6692959 (2004-02-01), Bennett et al.
patent: 6692960 (2004-02-01), Bennett et al.
patent: 6172186 (1994-06-01), None
patent: WO-94/09126 (1994-04-01), None
patent: WO-97/45439 (1997-05-01), None
patent: WO-99/67368 (1999-06-01), None
Braasch, D. A. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry. Apr. 2002; 41(14): 4503-4510.
Branch, A. D. A good antisense molecule is hard to find. Trends Biochem Sci. Feb. 1998;23(2):45-50.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. 1996. v 93, pp. 3161-3163.
Tamm, I. et al. Antisense therapy in oncology: new hope for an old idea. The Lancet. Aug. 2001, 358: 489-497.
Taylor, et al., “Antisense oligonucleotides: a systematic high-throuhput approach to target validation and gene function determination.”Drug Discovery Today. vol. 4 No. 12, Dec. 1999.
Accad et al., “Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1”,J. Clinical Invest. Mar. 2000 105(6):711-719.
Agrawal, S., “Antisense oligonucleotides: towards clinical trials”,TibtechOct. 1996 14:376-387.
Anderson et al., “Identification of a Form of Acyl-CoA:Cholesterol Acyltransferase Specific to Liver and Intestine in Nonhuman Primates”,J. Biol. Chem. Oct. 1998 273 (41):26747-26754.
Bocan et al., “The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits”,Arterioscelr Thromb Vasc. Biol. Jan. 2000 20:70-79.
Braasch et al., “Novel Antisense and peptide Nucleic Acid Strategies for Controlling Gene Expression”,BiochemistryApr. 2002 41(14):4503-4510.
Branch, A. D., “A good antisense molecule is hard to find”,Trends Biochem. Sci. Feb. 1998 23(2):45-50.
Buhman et al., “Mammalian acyl-CoA:cholesterol acyltransferases”,Biochimica et Biophysica ActaDec. 2000 1529(1-3):142-154.
Buhman et al., “Resistance to Diet-Induced Hypercholesterolemia and Gallstone Formation in ACAT2-Deficient Mice”,Nature MedicineDec. 2000 6(12):1341-1347).
Burnett et al., “Acyl coenzyme A:cholesterol acyltransferase inhibtion and hepatic apolipoprotein B secretion”,Clinica Chimica ActaAug. 1999 286(1-2):231-242.
Cases et al., “ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase”,J. Biol. Chem. Oct. 1998 273(41):26755-26764.
Chang et al., “Molecular Cloning and Functional Expression of Human Acyl-Coenzyme A:Cholesterol Acyltransferase cDNA in Mutant Chinese Hamster Ovary Cells”,J. Biol. Chem. Oct. 1993 268(28):20747-20755.
Chang et al., “Localization of Acyl Coenzyme A:Cholesterol Acyltransferase Gene to Human Chromosome 1q25”,Somatic Cell and Molecular GeneticsJan. 1994 20(1):71-74.
Chang et al., “Regulation and Immunolocalization of Acyl-Coenzyme A:Cholesterol Acyltransferase in Mammalian Cells as Studies with Specific Antibodies”,J. Biol. Chem. Dec. 1995 270(49):29532-29540.
Chang et al., “Acyl-coenzyme A:Cholesterol Acyltransferase”,Annu. Rev. Biochem. 1997 66:613-638.
Chang et al., “Immunological Quantification and Localization of ACAT-1 and ACAT-2 in Human Liver and Small Intestine”,J. Biol. Chem. Sep. 2000 275(36):28083-28092.
Chong et al., “Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis”,DrugsJul. 2000 60(1):55-93.
Davignon J., “Prospects for Drug Therapy for Hyperlipoproteinaemia”,Diabete&MetabolismeApr. 1995 21:139-146.
Dugar et al., “Amides of Piperidine, Morpholine and Piperazine Substituted 1-Phenylethylamines:Inhibitors of AcylCoA:cholesterol Acyltransferase (ACAT) Activityin vitroandin vivo”, Bioorganic&Medicincal ChemistrySep. 1995 3(9):1231-1326.
Farese R.V. Jr., “Acyl CoA:cholesterol acyltransferase genes and knockout mice”,Curr Opin LipidolApr. 1998 9(2):119-123.
Fazio et al., “Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages”,J. Clin. Invest. Jan. 2001 107(2):163-171.
Fritz et al., “Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides”,J. Coll. Interface Sci. Nov. 1997 195:272-288.
Gewirtz et al., “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise”,Proc. Natl. Acad. Sci. Apr. 1996 93:3161-3163.
Krause et al., “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-A Theroschlerotic Activities in Experimental Animals” inInflammation: Mediators and Pathways ACAT Inhibitors, Ruffalo et al., Eds. CRC Press, Boca Raton 1995 Chapter 6:173-197.
Lee et al., “Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) as Hypocholesterolemic Agents: Synthesis and Structure-Activity Relationships of Novel Series of Sulfonamides, Acylphosphonamides and Acylphosphoramidates”,Bioorganic&Medicinal ChemistryFeb. 1998 8(3):289-294.
Lee et al., “Cholesterol-Lowering Activity of Naringenin via Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Acyl Coenzyme A:Cholesterol Acyltransferase in Rats”,Ann Nutr Metab1999 43(3):173-180.
Li et al., “Human Acyl-CoA:Cholesterol Acyltransferase-1 (ACAT-1) Gene Organization and Evidence That the 4.3-Kilobase ACAT-1 mRNA Is Produced from Two Different Chromosomes”,J. Biol. Chem. Apr. 1999 274(16):11060-11071.
Matsuda K., “ACAT Inhibitors as Antiatherosclerotic Agents: Compounds and Mechanisms”,Medicinal Research ReviewsMay 1994 14(3):271-305.
Matsuda et al., “Activation of acyl-coenzyme A:cholesterol acyltransferase activity by cholesterol is not due to altered mRNA levels in HepG2 cells”,Biochimica et Biophysica ActaMay 1996 1301(1-2):76-84.
Meiner et al., “Disruption of acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggestin multiple cholesterol esterification enzymes in mammals”,Proc. Natl. Acad. Sci. USANov. 1996 93:14041-14046.
Meiner et al., “Tissue expression studies on the mouse acyl-CoA:cholesterol acyltransferase gene (ACAT): findings supporting the existence of multiple cholesterol esterification enzymes in mice”,J. Lipid ResearchSep. 1997 38(9):1928-1933.
Nicolosi et al., “ The ACAT inhibitor, CI-1011 is effective in the preventive and regression of aortic fatty streak area in hamsters”,AtherosclerosisMar. 1998 137(1):77-85.
O'Brien et a
Crooke Rosanne M.
Graham Mark J.
Tarbet Kristina Lemonidis
Gibbs Terra C.
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals Inc. Patent Department
Knobbe, Martns, Olson & Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of acyl CoA cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of acyl CoA cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of acyl CoA cholesterol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730543